Targeting B7-H3 in prostate cancer: Phase 2 trial in localized prostate cancer using the anti-B7-H3 antibody enoblituzumab, with biomarker correlatives.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Eugene Shenderov, Angelo M De Marzo, Tamara L. Lotan, Hao Wang, Su Jin Lim, Mohamad E. Allaf, Paul A. Moore, Francine Chen, Kristina Sorg, Andrew M White, Briana Hudson, Paul A. Fields, Shaohui Hu, Samuel R. Denmeade, Kenneth J. Pienta, Christian P. Pavlovich, Charles G. Drake, Drew M. Pardoll, Emmanuel S. Antonarakis
Institutions: Johns Hopkins University, Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, MacroGenics (United States), Nanostring Technologies (United States), Adaptive Biotechnologies (United States), Herbert Irving Comprehensive Cancer Center, Masonic Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Conquer Cancer Foundation
OpenAlex ID: W4286297271